Investor Presentaiton

Expanding opportunity Significant capital needs Innovative funding Facilitating M&A Differentiated sourcing Effectively reaching significant majority of potential partners Meetings in Royalty Pharma network 66% 79% Companies Phase 2 or later >$500m Companies Phase 3 or later >$1bn Market cap Meetings with 79% of companies Phase 3 or later >$1bn market cap Meetings with 66% of companies Phase 2 or later >$500m market cap, cultivating relationships for future potential partnerships Further expand outreach capabilities and calling frequency Strategic plan to develop the market for synthetic royalties through greater awareness and education ROYALTY PHARMA Source: FactSet, Evaluate and Bloomberg. Data set includes 450 public biopharma companies. Analysis done as of May 2022. 43 33

View entire presentation